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Introduction. The molecular and cellular mechanisms involved in prostate cancer progression
towards a hormone-independent and highly invasive, metastatic phenotype, are not well
understood. Cell lines with different metastatic potential, when analyzed by microarray
techniques, offer valuable tools for identifying genes associated with the metastatic phenotype.
Objectives. Gene expression profiles were compared for two rat prostate cancer cell lines
with differing metastatic abilities in order to better characterized molecular underpinnings of
the prostate cancer metastatic process.
Materials and methods. Affymetrix arrays were used to analyze gene expression of two rat
prostate cancer cell lines, MAT-LyLu and G.  Microarray data were analyzed using pathway
and functional group analysis.  A selected set of genes was subjected to real-time polymerase
chain reaction for validating the microarray data.
Results. Microarray data analysis revealed differential expression of genes from a number of
signaling and metabolic pathways. Overexpression was detected in 48 genes and
underexpression in 59 genes of the MAT-LyLu line compared to the standard G line. Genes
were grouped into functional categories, including epithelial-extracellular matrix interaction,
cell motility, cell proliferation, and transporters, among others. Many of these genes were not
previously associated to prostate cancer metastasis.
Conclusions. Many genes with altered expression associated with a metastatic prostate cancer
phenotype were identified. Further validation of these genes in human prostate samples will
determine their usefulness as biomarkers for early diagnosis of recurrence or metastasis of
prostate cancer, as well as potential therapeutic targets for this disease.
Key words: carcinoma, neoplasm metastasis, gene expression, biological markers,
extracellular matrix, microarray analysis.
Análisis de micromatrices de ADN revela genes asociados a metástasis en líneas
celulares de cáncer de próstata de rata
Introducción. Los mecanismos moleculares y celulares involucrados en la progresión del
cáncer de próstata hacia un fenotipo metastásico no son bien entendidos. El análisis molecular
de líneas celulares con diferentes potenciales metastásicos ofrece un instrumento valioso
para identificar genes asociados al fenotipo metastásico.
Objetivos. Comparar los perfiles de expresión genética de dos líneas celulares de cáncer de
próstata de rata con diferentes capacidades metastásicas para un mejor entendimiento del
proceso metastásico.
Materiales y métodos. Se utilizaron micromatrices de Affymetrix para analizar la expresión
génica de dos líneas celulares de próstata de rata con diferentes propiedades metastásicas,
MAT-LyLu y G. Los datos fueron analizados en el contexto de vías y grupos funcionales. Se
utilizó reacción en cadena de la polimerasa en tiempo real para validación de genes
seleccionados.
Resultados. Además de la expresión diferencial de genes en un número de vías de
señalización y metabólicas, se detectó sobre-expresión de 48 genes y expresión disminuida
de 59 genes en la línea MAT-LyLu comparado con la línea G. Los genes fueron agrupados en
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categorías funcionales, tales como interacción epitelial-matriz extracelular, motilidad celular,
proliferación celular, y transportadores, entre otros. Muchos de estos genes no han sido
asociados previamente a la metástasis del cáncer de próstata.
Conclusiones. Se identificaron genes con expresión alterada asociados al fenotipo metastásico
del cáncer de próstata. La subsiguiente validación de estos genes en tejido prostático humano
pudiera revelar su utilidad como marcadores biológicos para esta enfermedad.
Palabras clave: carcinoma, metástasis de la neoplasia, expresión génica, marcadores
biológicos, matriz extracelular, análisis de micromatrices.
The American Cancer Society estimates that
234,460 new cases of prostate cancer were ex-
pected in the United States in 2006, representing
the most common cancer in men and the third
leading cause of male cancer-related deaths (1).
Treatments for prostate cancer including surgical
and hormonal therapies, have shown beneficial
effects only for early-stage, hormone-dependent
disease. However, for more advanced stages, the
cancer cells become hormone-independent and
highly invasive, until they reach an incurable clini-
cal stage associated with an increased incidence
of metastases, especially to the bone. The mo-
lecular and cellular mechanisms involved in this
process are not well understood (2).
Dunning rat tumor cell sublines of variable
metastatic potential: G (non metastatic) and MAT-
LyLu (highly metastatic) were used to investigate
the differences in gene expression associated to
metastatic prostate cancer. These two cell lines
were derived from the same parental tumor, the
Dunning R-3327 from Copenhagen rats (3). The
R3327-G, or simply G, cell line is a poorly
differentiated, androgen-dependent tumor line
obtained in Dunning’s laboratory after in vitro
passaging of the original tumor. The MAT-LyLu
(Metastatic At-Lymph Node and Lung) cell line was
developed at Johns Hopkins School of Medicine
and  characterized  by Isaacs et al (4,5). The G
and MAT-LyLu cell l ines exhibit many
characteristics seen during the progression of
human prostate cancer, including androgen
responsiveness and differential metastatic ability,
representing a well characterized model to study
the metastatic process (6,7).
In the current study, the gene expression profiles
of the two rat cell lines were determined with
Affymetrix DNA microarrays (GeneChip Rat Ge-
nome U34A array). There was altered expression
(overexpression and underexpression) of 107
genes in the MAT-LyLu cell line was compared to
the G cell line. Several of the genes were not pre-
viously associated with prostate cancer metasta-
sis. Validation of these metastasis-associated
genes in human prostate samples have a poten-
tial application as biomarkers for early diagnosis
of recurrence or metastasis or as therapeutic tar-
gets for this disease.
Materials and methods
Cell lines
Dunning rat tumor cell sublines, G (non meta-
static) and MAT-LyLu (highly metastatic) were
grown using RPMI 1640 media supplemented with
10% fetal bovine serum (FBS), 1% L-glutamine,
and 1% penicillin-streptomycin at 37oC in a hu-
midified atmosphere containing 5% CO2. Cells
were grown in T-75 culture flasks with 25 cc of
growth media. All tissue culture work was done in
a Class IIA cell culture hood with 20 min of UV
light and ethanol wash between handling of the
different cell lines.
Total RNA isolation
Total RNA was prepared from MAT-LyLu and G
cells grown to approximately 75% confluence us-
ing Trizol solution (Invitrogen) and stored as an
ethanol precipitate. The resulting RNA concentra-
tion was measured spectrophotometrically, and
quality was assessed by the 260/280 ratio and
agarose gel electrophoresis. Two biological repli-
cates (duplicates)consisted of RNA samples  ob-
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tained from cells grown at different dates and
processed independently for microarray experi-
ments (no sample pooling was done before
microarray hibridizations). In this manner,
microarray hybridization for each cell line was
performed in duplicate.
Microarrays
To study the gene expression profile of these rat
cell l ines, the Rat Genome U34A Array
(Affymetrix, Santa Clara, CA) was used.  This array
represented approximately 7,000 full-length gene
sequences and approximately 1,000 EST clus-
ters consisting of expressed sequence tags-tran-
scribed sequences of unknown function.
Microarray procedures
Total RNA was processed at the University DNA
Microarray Facility of the Center for Molecular
Medicine at the SUNY Stony Brook School of
Medicine, according to protocols described in
Affymetrix GeneChip Expression Analysis tech-
nical manual (Affymetrix, Santa Clara, CA). The
manual can be downloaded from the Affymetrix
website (http://www.affymetrix.com/ support/tech-
nical/manual/expression_manual.affx). RNA qual-
ity was first assessed by electrophoresis using
the Agilent Bioanalyzer 2100 and spectrophoto-
metric analysis. Then, total RNA from each
sample was used to generate high fidelity cDNA.
Briefly, first-strand cDNA was reverse transcribed
from 15 µg of total RNA using 600 U of SuperScript
II RT (Invitrogen) in a 20-µl total volume contain-
ing T7-(dT)24 primer, 10 mM DTT, 500 µM of each
dNTP, and 1x first-strand cDNA buffer for 1 h at
42°C. Second-strand cDNA was synthesized in
1x reaction buffer containing 200 µM of each dNTP,
10 U of DNA ligase, 40 U of DNA polymerase I,
and 2 U of RNase H (final volume = 150 µl) for 2 h
at 16°C. Samples were then treated with 20 U of
T4 DNA polymerase for 5 min at 16°C and incu-
bated in 10 µl of 0.5 M EDTA. Double-stranded
cDNA was purified with phase lock gel electro-
phoresis (Eppendorf Scientific, Westbury, NY) and
phenol-chloroform extraction, followed by ethanol
precipitation. Upon completion of cDNA synthe-
sis, 1µg of product was converted to biotinylated
cRNA using the Enzo BioArray HighYield RNA
Transcript Labeling Kit. Labeled cRNA was frag-
mented and hybridized to the Affymetrix oligo-
nucleotide GeneChip rat U34A arrays. Twelve mi-
crograms of biotinylated target cRNA were hybrid-
ized per microarray. Then, the gene chips were
automatically washed, to remove non-specifically
bound cRNA, and stained with streptavidin-phy-
coerythrin conjugate in the GeneChip Fluidics Sta-
tion. Washed arrays were automatically scanned
using Hewlett-Packard GeneArray Scanner
equipped with an argon ion laser. The methodol-
ogy used for the microarray procedure follows the




Scanned output files were analyzed with dChip
v1.3 software (www.dchip.org ) and Affymetrix
MicroArray Suite 5.0 (MAS 5.0) software. First,
arrays were normalized by dChip v1.3 using the
invariant set normalization method (8). After nor-
malization, model-based gene expression esti-
mates and outlier detection algorithm were ob-
tained according to the perfect-match-only model
performed by Li-Wong (9); transcripts regarded as
outliers were excluded for further analysis.
Affymetrix MAS 5.0 software was used to deter-
mine if the transcripts were detected as present,
absent, marginal, or no call. For significant ex-
pression level, a cut off value of 500 units was
used. DNA microarray data generated from MAT-
LyLu samples were compared to microarray data
from G samples using dChip v1.3 software and
the resulting expression analysis files were sub-
jected to biological pathway and functional group
analysis to determine the significance of changes
at the biological context.
Pathway analysis
To identify biological pathways playing a role in
the metastatic process, the microarray data were
analyzed with the GenMAPP (Gene Map Annota-
tor and Pathway Profiler) and MAPPFinder pro-
grams developed at the Gladstone Institutes at
the University of California at San Francisco (10)
(www.genmapp.org). Criteria used for GenMAPP/
MAPPFinder analysis for increased expression
were a minimum average intensity of 500 units, a
% present (P) call of 100, and a fold change >1.8
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in the MAT-LyLu cell line compared to the G cell
line. Criteria for decreased expression were a mini-
mum intensity of 500 units, a % P call of 100, and
a fold change of <-1.8 in the MAT-LyLu cell line
compared to the G cell line. The programs gener-
ated a Z score based on the hypergeometric dis-
tribution.
Functional group analysis
The catalog of characterized genes is incomplete
in the context of biological pathways, and many
genes are of unknown function. Therefore a func-
tional group analysis was performed in order to
have a more complete picture of genes associ-
ated to the metastatic phenotype and to increase
the possibilities of finding genes not previously
associated to prostate cancer metastasis. For
functional group analysis, the dChip v1.3 software
provided a means for comparing the MAT-LyLu
microarray data vs. G microarray data., It gener-
ated a gene list that contained genes with P <0.05
(from t-test), a fold change > + 2.0, and a % P call
of 100.These genes were thereby identified as
having significantly altered expression (either
overexpression or underexpression). This set of
genes was subjected to hierarchical clustering
(dChip v1.3) using the Pearson correlation met-
ric. Before clustering, the expression value for a
gene across all samples was standardized to have
a mean of 0 and standard deviation of 1. dChip
v1.3 also determined in all branches the presence
of local clusters enriched by genes having a par-
ticular function (functional clusters), according to
gene ontology (GO) terms (11). In this way, co-
expressed genes were detected that shared simi-
lar functions relevant to prostate cancer metasta-
sis. dChip v1.3 also generated a p value for func-
tional clusters with significance set at p<0.01.
Real time PCR
Quantitative real time PCR (qRT-PCR) was per-
formed for selected genes with the same individual
RNAs used in microarray experiments in order to
validate the technique (12). Gene-specific prim-
ers were designed with Primer3 software for kelch
repeat 1 (krp1) (forward primer = AAGGAGATGGC-
GCTA GACAA; reverse primer = CACGGCCTC-
AAAT ACCACTT), endothelial cell-specific mol-
ecule 1(ESM-1) (forward primer = CTACTTTG
GACGGCTGCTTC; reverse primer = CGTCACC
GAAATCATCTTCC) and caveolin-1 (CAV-1) (for-
ward primer = TGAAGATGTGAT TGCGG AAC;
reverse primer = ATCTCTT CCTGCGTGCTGAT).
One microgram total RNA was reverse transcribed
using oligo-dT and the Reverse Transcription Sys-
tem kit (Promega). Two microliters of reverse tran-
scribed product was subjected in triplicate to qRT-
PCR using the LightCycler DNA Master SYBR
Green system (Roche Molecular Biochemicals,
Mannheim, Germany). PCR was performed in a
LightCycler (Roche, Mannheim, Germany) with a
2 min pre-incubation at 95°C followed by 40 cycles
of amplification steps. PCR products were sub-
jected to melting curve analysis to verify that no
amplification of non-specific products had oc-
curred. In each qRT-PCR run, a standard curve
was generated using a serial dilution of a cDNA
standard identical in size and sequence to the
target gene fragment to be amplified. Serial dilu-
tion ranged from 0.01 to 100 pg of the standard
cDNA fragment. The standard curve was calcu-
lated by the Light Cycler 5.32 software (LC-Run
Version 5.32, Roche) by regression of the cross-
ing points of the PCR curves from the dilution
series of the standard cDNA fragment. Changes
in gene expression were quantified by calculating
the average value of the triplicate reactions from
the MAT-LyLu cell line and comparing that to the
average derived from the triplicate reactions from
the G cell line. The GAPDH gene was chosen as
a control housekeeping gene for normalization,
since no change in the GAPDH mRNA levels oc-
curred across the entire sample set (MAT-LyLu
and G samples). Statistical significance of
changes was determined by t-test.
Statistical methods
For DNA microarray and qRT-PCR analyses, a p
<0.05  from t-test (two-sided) was considered sta-
tistically significant. For hierarchical clustering,
significant functional cluster p values were calcu-
lated using the hyper-geometric distribution. For
pathways analysis with GenMAPP/MAPPFinder
programs, the Z score based on the hypergeo-
metric distribution was used. The Z score reflected
the significance of changes and it falls in a range
of positive to negative values. A cut-off value of
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Figure 1. Hierarchical clustering: overexpressed genes (red
color) in MAT-LyLu (MLL).The figure representing the
hierarchical clustering was automatically generated by dChip
v1.3 software (www.dchip.org) using the Pearson correlation
metric. The 20 most overexpressed genes are shown.
2.0 was selected for the Z score, representing the
equivalent of p= 0.05 for the hypergeometric dis-
tribution. Z scores were  generated automatically
by the programs.
Results
Many differentially expressed genes were
identified from several signaling and metabolic
pathways in MAT-LyLu (Table 1). Among the
signaling pathways, differential expression was
found in the androgen receptor signaling pathway,
focal adhesion, Wnt- signaling, hepatocyte growth
factor receptor (HGF), epidermal growth factor
(EGF) receptor 1, MAPK, integrin mediated cell
adhesion, TGF beta, and Insulin signaling pathways
(Table 1). In addition to signaling pathways, a
number of genes were overexpressed in the
cholesterol biosynthesis and nucleotide metabolic
pathways (Table 1). Overexpression of these
metabolic pathways may account for the high
metabolic activity required for the MAT-LyLu cell
line to maintain its characteristic high level of cell
proliferation compared to the non-metastatic G
line, which has a much lower doubling time (4,13).
On the other hand, functional group analysis of
the DNA microarray data revealed the significantly
altered expression of 107 well-characterized genes
(Table 2), 48 overexpressed and 59
underexpressed in MAT-LyLu compared to G cell
lines, according to the criteria described in
materials and methods.
Hierarchical clustering of the significantly ex-
pressed genes clearly showed the gene expres-
sion differences between MAT-LyLu and G cell
lines (Figure 1). Significant functional clustering
of the differentially expressed genes included the
following GO categories: extracellular region/ex-
tracellular matrix (20% of the genes), development
(5%), defense response (7%), proteolysis and
peptidolysis (5%) and magnesium ion binding
(5%), among others.
Some of these functional clusters reflected the
changes believed to occur during the metastatic
process, such as alteration of extracellular matrix
components, neovascularization, changes in cell
structure and increased motility (14). Thus, there
is a strong concordance of our results with the
scientific literature about the metastatic process.
We also compared our microarray data with other
microarray analysis of prostate cancer metasta-
sis (15,16). For example, in the study by LaTulippe
et al, they reported the altered expression of sev-
eral genes that correlate with the metastatic phe-
notype in prostate cancer and those genes were
grouped into functional categories, such as cell
cycle regulation, DNA repair, cell structure, and
motility among others. Although we cannot corre-
late directly the results presented by LaTulippe et
al (clinical samples) with our results (rat cell lines
samples), those results by LaTulippe et al showed
a similar trend of changes in the metastatic pros-
tate cancer than our data (Table 2), demonstrat-
ing the validity of our approach and the signifi-
cance of our results.
For specific gene validation, two approaches were
used-correlation with gene expression database
results and with qRT-PCR analysis. In this way,
the data were matched with the Cancer Genome
Anatomy Project database (cgap.nci.nih.gov) and
with the Prostate Expression database (17).  Each
gene was first matched with the corresponding
human gene using the Entrez Gene identification
number, since the databases are for Homo sapi-
ens species. Table 2 indicates the many genes
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Table 1. GenMAPP/MAPPFinder pathway analysis of differentially expressed genes in the MAT-LyLu cell line compared to
the G cell line. Signaling and Metabolic Pathways that showed significant differential expression in the MAT-LyLu cell line
compared to the G cell line (Z score > 2.0). After GenMAPP/ MappFinder analysis, pathways were ranked based on the Z
score and percentage of genes changed. The cut-off value chosen for Z score was 2.0 (equivalent to p =0.05 for the
hypergeometric distribution). The number and percentage of genes changed in each pathway and the corresponding Z
score were calculated with the MAPPFinder program.
A. Signaling pathway/ Entrez Fold  % Z
     individual genes gene change changed score
Androgen receptor 17 3.3
Cav (Caveolin 1) 25404 31.05
Pten (phosphatase and tensin homolog) 50557 6.64
Mdm2_predicted 314856 1.81
Pxn (paxillin) 360820 2.92
Cyclin D1 58919 7.95
Caspase 1 25166 -11
Focal Adhesion 14 3.3
fibronectin 1 25661 3.4
laminin, alpha 3 286966 2.47
Spp1 (secreted phosphoprotein 1) 25353 4.1
Cav (Caveolin 1) 25404 31.05
Cav3 (caveolin 3) 29161 -2.3
Ptk2 (protein tyrosine kinase 2,  Focal adhesion kinase 1, FAK) 25614 -2.0
Pxn (paxillin) 360820 2.92
Pten (phosphatase and tensin homolog) 50557 6.64
Rock2 (Rho-associated coiled-coil forming kinase 2) 25537 2.2
Cyclin D1 58919 7.95
Ccnd3 (cyclin D3) 25193 -4.7
Sepp1 (selenoprotein P) 29360 -23.0
Mapk6(mitogen-activated protein kinase 6) 58840 3.1
Wnt signaling 25 3.6
Prkcd (protein kinase C, delta) 170538 2.28
Fzd1 (frizzled homolog 1) 58868 -2.57
Fzd2 (frizzled homolog 2 ) 64512 -3.77
Cyclin D1 58919 7.95
Ccnd3 (cyclin D3) 25193 -4.7
Fosl1 (fos-like antigen 1) 25445 14.5
Plau (plasminogen activator, urokinase) 25619 4.68
Hepatocyte growth factor receptor 24 3.5
Met (met proto-oncogene:Hepatocyte growth factor receptor) 24553 2.57
Pten (phosphatase and tensin homolog) 50557 6.64
Pxn (paxillin) 360820 2.92
Ptk2 (protein tyrosine kinase 2) 25614 -2.0
Map2k2 (mitogen activated protein kinase kinase 2) 58960 -1.8
Epidermal growth factor receptor 1 13 2.6
Arf4 (ADP-ribosylation factor 4) 79120 1.71
Cav (Caveolin 1) 25404 31.05
Gja1(gap junction membrane channel protein alpha 1) 24392 10.53
Kras (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) 24525 -1.8
Ddef1_predicted (development and differentiation enhancing, 314961 -2.7
predicted) Krt2-8 (keratin complex 2, basic, gene 8) 25626 22.6
Pxn (paxillin) 360820 2.92
Dnm1(dynamin 1) 140694 -1.84
Ptpn12 (protein tyrosine phosphatase, non-receptor type 12) 114856 1.85
Dusp1 (dual specificity phosphatase 1) 114856 -2.3
Stat1(signal transducer and activator of transcription 1) 25124 -3.23
Stat2 (signal transducer and activator of transcription 2) 288774 -2.3
MAPK signaling pathway 12.6 2.5
Kras (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) 24525 -1.8
Map2k2 (mitogen activated protein kinase kinase 2) 58960 -1.8
Map3k2 25579 1.93
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Prkcd (protein kinase C, delta) 170538 2.28
Casp1 (caspase 1) 25166 -11.1
Mapk6(mitogen-activated protein kinase 6) 58840 3.1
Arrb1 (arrestin, beta 1) 25387 1.74
Ppm1a (protein phosphatase 1A, magnesium dependent, alpha isoform) 24666 2.52
Hspb1 (heat shock 27kDa protein 1) 24471 -3.75
Ddit3 (DNA-damage inducible transcript 3) 29467 -2.45
Dusp5 (dual specificity phosphatase 5) 171109 2.35
Dusp6 (dual specificity phosphatase 6) 116663 11.08
Integrin mediated cell adhesion 14.2 2.3
Pxn (paxillin) 360820 2.92
Cav1(caveolin 1) 25404 31.05
Cav3 (caveolin 3) 29161 -2.3
Ptk2 (protein tyrosine kinase 2) 25614 -2.0
Rock2 (Rho-associated coiled-coil forming kinase 2) 25537 2.2
Mapk6(mitogen-activated protein kinase 6) 58840 3.1
Map2k2 (mitogen activated protein kinase kinase 2) 58960 -1.8
Sepp1 (selenoprotein P) 29360 -23.0
Itga7 (integrin alpha 7) 81008 2.93
Capn2 (calpain 2) 29154 2.34
TGFbeta signaling 16 2.1
Tgfb1 (transforming growth factor, beta 1) 59086 2.53
Ltbp1 (latent transforming growth factor beta binding protein) 59107 4.79
Fst (follistatin) 24373 5.91
Stat1 (signal transducer and activator of transcription 1) 25124 -3.23
Serpine2 (serine (or cysteine) peptidase inhibitor, clade E, member 2) 29366 8.61
Sepp1 (selenoprotein P) 29360 -23.0
Insulin signaling 11.4 2.0
Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) 24778 1.93
Stx4a (syntaxin 4A (placental) 81803 2.37
Arf6 (ADP-ribosylation factor 6) 79121 4.53
Rhoj (ras homolog gene family, member J) 299145 -1.92
Egr1 (early growth response 1) 24330 2.39
Pten | phosphatase and tensin homolog 50557 6.64
Prkcd (protein kinase C, delta) 170538 2.28
Prkaa2 (protein kinase, AMP-activated, alpha 2 catalytic subunit) 78975 -7.7
Mapk6(mitogen-activated protein kinase 6) 58840 3.1
Map3k12 (mitogen activated protein kinase kinase kinase 12) 25579 1.93
B. Metabolicpathway/ Entrez Fold  % genes Z
    individual genes gene change changed score
Cholesterol biosynthesis 53 6.8
Hmgcs1 (3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1) 29637 6.65
Hmgcr (3-hydroxy-3-methylglutaryl-Coenzyme A reductase) 25675 3.49
Fdps (farnesyl diphosphate synthase) 83791 4.06
Sc4mol (sterol-C4-methyl oxidase-like) 140910 16.15
Cyp51 (cytochrome P450, subfamily 51) 25427 3.84
Sqle (squalene epoxidase) 29230 3.23
Sterol biosynthesis 45 5.1
Hmgcr (3-hydroxy-3-methylglutaryl-Coenzyme A reductase) 25675 3.49
Fdps (farnesyl diphosphate synthase) 83791 4.06
Nqo1(NAD(P)H dehydrogenase, quinone 1) 24314 2.14
Sqle (squalene epoxidase) 29230 3.23
Nucleotide metabolism 30 2.9
Prps1 (phosphoribosyl pyrophosphate synthetase 1) 29562 8.25
Prps2(phosphoribosyl pyrophosphate synthetase 2) 24689 5.37
Hprt (hypoxanthine guanine phosphoribosyl transferase) 24465 16.53
A. Signaling pathway/ Entrez Fold  % Z
     individual genes gene change changed score
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were expressed in cancer and/or in prostate
samples.
For qRT-PCR analysis, we chose the krp1, ESM-
1 and CAV-1 genes were chosen because they
represented overexpressed genes relevant to the
current study. These genes were validated by qRT-
PCR with statistically significant p values (< 0.05)
(Table 3). The levels of gene expression deter-
mined by qRT-PCR analyses were consistent with
those observed in the DNA microarray experi-
ments. For example, the 36- fold increase in ex-
pression of krp1 determined by DNA microarray
analysis was validated by the 48-fold increase
observed by qRT-PCR. These results validated
our DNA microarray analysis.
Discussion
Prostate cancer progression from a localized form
to a metastatic state seems to be regulated by
several oncogenic signals in the prostate epithe-
lial cells and by changes in the stromal-epithelial
interaction.  These include the Hedgehog signal-
ing and Wnt signaling pathways (18,19) as well
as overexpression of several growth factors and
their receptors, such as the epidermal growth fac-
tor, fibroblast growth factor, HGF, insulin-like
growth factor-1 and vascular endothelial growth
factor (VEGF) (20). In agreement with published
observations, the metastatic phenotype of MAT-
LyLu cell line was associated to overexpression
of genes involved in several of these signaling
pathways. Examples of the overexpressed genes
included met proto-oncogene (HGF receptor),
phosphatase and tensin homologue on chromo-
some 10 (PTEN), paxillin (Pxn), and caveolin
(Cav)-all of which are important components of
the HGF receptor, androgen receptor, epidermal
growth factor receptor, integrin mediated cell ad-
hesion, and focal adhesion signaling pathways
(Table 1).
The HGF receptor, also called c-Met, is a
heterodimer with tyrosine kinase activity that as-
sociates with a multiprotein complex involved in
downstream signal transduction (21).
c-Met is activated by the HGF and it has been
shown to induce alterations in cell motility, cell
shape, adhesion, resistance to apoptosis, and
anchorage independent growth. These all contrib-
ute to the role of c-Met in cancer and makes this
receptor a potential therapeutic target for cancer
drugs (22-24).  c-Met has also been found to tar-
get paxillin (overexpressed in the current study)
and focal adhesion kinase (FAK), an activity that
can lead to alterations in cell motility and tissue
invasion by transformed cells (25,26). The
overexpression of several genes in the HGF re-
ceptor pathway in the MAT-LyLu cell line (Table1)
was also notable.
The clinically aggressive phenotype distinctive of
the metastatic cascade (14), has been studied at
the gene expression level (15,16). In those studies,
the overall gene expression alteration in the
metastatic phenotype agrees with the data
herein, with similar patterns of altered expression
in genes associated with signaling transduction,
ECM remodeling, motility, cell cycle regulation,
and cell structure. An important validation of the
cell line base model used herein are results from
studies (15,16) done in human samples which fully
agree with the MAT-LyLu data.
Genes relevant for the metastatic phenotype,
found with altered expression in the current study,
include ESM-1, CD24 antigen, biglycan (BGN),
serpine2, fibromodulin, macrophage stimulating 1,
alpha-2-macroglobulin, glycoprotein 38, decorin,
vascular cell adhesion molecule 1, clusterin, and
elastin. These 12 genes are grouped in the ECM
interaction functional group. Several of these
genes encode proteoglycan (PG) proteins (ESM-
1, BGN, fibromodulin, and decorin) which are major
components of the ECM that maintain the integrity
of structural tissue. However, ESM-1, BGN and
fibromodulin have not been associated previously
with prostate cancer metastasis. Furthermore, the
most overexpressed gene in MAT-LyLu, krp1-
which encodes a protein associated with formation
of elongated pseudopodia in transformed rat
fibroblast (27)-has not been previously associated
to prostate cancer metastasis. Additional studies
are necessary to determine the association of
these genes to prostate cancer metastasis in the
human counterpart. Currently experiments are
underway in our laboratory to determine the status
of expression of ESM-1 gene and protein in human
prostate cancer.
198
Biomédica 2007;27:190-203Reyes I, Tiwari R, Geliebter J et al
Table 2. Significant differentially expressed genes in the Mat-LyLu cell line compared to the G cell line. Positive fold changes
indicate overexpression of the gene in Mat-LyLu; negative fold changes indicate underexpression. P value from T-test (two-
sided).Genes were grouped into functional categories according to GO classifications.
Functional Group/ Entrez Fold P value
 individual genes gene change
Extracellular/ECM
Endothelial cell-specific molecule 11 64536 26.5 0.014186
Protein tyrosine phosphatase, receptor type, Q 360417 19.72 0.011614
CD24 antigen1,2 25145 15.56 0.030306
Gap junction membrane channel protein alpha 11 24392 10.53 0.037434
Transmembrane 4 superfamily member 3 171048 10.4 0.016358
Serpine21,2 29366 8.61 0.006009
Activated leukocyte cell adhesion molecule1,2 79559 6.65 0.009178
Fibromodulin1 64507 2.62 0.010866
Plasminogen activator inhibitor 2 type A1 60325 2.11 0.005814
Procollagen, type XII, alpha 11 25683 -2.18 0.005956
Glycoprotein Ib (platelet), beta polypeptide 116727 -2.5 0.017437
Macrophage stimulating 1 (hepatocyte growth factor-like)1 24566 -2.61 0.007459
Alpha-2-macroglobulin1,2 24153 -3.8 0.007349
Hyaluronan and proteoglycan link protein 11 29331 -3.82 0.011615
Glycoprotein 38 54320 -3.87 0.015588
Decorin 29139 -5.74 0.00339
Vascular cell adhesion molecule 11 25361 -7.82 0.012319
Clusterin1 24854 -8.84 0.000569
Elastin1 25043 -12.76 0.002621
Biglycan1,2 25181 -13.23 0.023713
Selenoprotein P, plasma, 11,2 29360 -23.08 0.025153
Cell motility
Kelch repeat and BTB (POZ) domain containing 10 (krp1)1 117537 36.21 0.031316
Defense response
Preproenkephalin, related sequence 29237 24.63 0.002009
Sialophorin1 24796 24.14 0.020209
T-cell receptor gamma chain1 24821 -2.2 0.013275
Myxovirus (influenza virus) resistance 21 286918 -2.22 0.005247
Major histocompatibility complex, class II, DM alpha1 294274 -2.37 0.012974
MHC class Ib RT1.S31 294228 -4.8 0.027941
RT1 class Ib, locus Aw2 24737 -5.18 0.025273
Similar to interferon regulatory factor 7 (LOC293624), mRNA 293624 -6.14 0.030563
Development
Thymosin beta-41 81814 19.82 0.003524
Glutamate receptor interacting protein 11 84016 8.4 0.045733
Synuclein, gamma1 64347 6.62 0.01336
Late gestation lung protein 11 171547 -2.26 0.022152
Transgelin1 25123 -5.72 0.028973
Magnesium ion binding
Hypoxanthine guanine phosphoribosyl transferase 24465 11.45 0.021844
Phosphoribosyl pyrophosphate synthetase 11,2 29562 8.25 0.010677
Phosphoribosyl pyrophosphate synthetase 21 24689 5.37 0.000847
UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 61 65196 3.4 0.009301
Ectonucleoside triphosphate diphosphohydrolase 21 64467 -2.7 0.022148
MAP kinase phosphatase activity
Dual specificity phosphatase 51 171109 2.35 0.01035
Dual specificity phosphatase 11 114856 -2.3 0.005724
Oxidoreductase activity
Cytochrome P450, family 3, subfamily a, polypeptide 131 171352 14.28 0.010339
1Genes found in the Cancer Genome Anatomy Project
2Genes found in the Prostate Expression database
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Functional Group/ Entrez Fold P value
 individual genes genes change
3-hydroxy-3-methylglutaryl-Coenzyme A reductase1 25675 3.49 0.011653
Branched chain keto acid dehydrogenase E1, beta polypeptide 29711 2.14 0.006807
Cytochrome P450, subfamily 24 25279 2.11 0.040331
Cytochrome b-245, alpha polypeptide1,2 79129 -3.64 0.024939
3-alpha-hydroxysteroid dehydrogenase 191574 -4.86 0.015007
Proteolysis and peptidolysis
Plasminogen activator, urokinase1 25619 4.68 0.017576
Cathepsin S1 50654 -2.33 0.009061
Alanyl (membrane) aminopeptidase1,2 81641 -3.18 0.022316
Dipeptidase 1 (renal) 94199 -6.82 0.035748
Caspase 11 25166 -11.12 0.018091
Regulation of cell cycle /proliferation
Caveolin 11,2 25404 31.05 0.0005
Cyclin D11,2 58919 7.95 0.00532
B-cell translocation gene 31 54230 -17.35 0.039715
CD 81 antigen1 25621 -36 0.048536
Regulation of transcription/ DNA-binding
High mobility group AT-hook 11 117062 15.41 0.001102
Cxxc5 292770 4.25 0.008338
HNF-3/forkhead homolog-1 64826 3.08 0.009154
Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA 291670 -2.28 0.008314
Nuclear receptor subfamily 4, group A, member 2 54278 -2.62 0.020084
LIM homeobox protein 21 117555 -5.43 0.046292
Transporter activity
Fatty acid binding protein 4, adipocyte1 79451 34.02 0.006713
Fatty acid binding protein 5, epidermal1 140868 15.38 0.049212
Rabin 3 29885 6.46 0.023285
Lectin, galactose binding, soluble 91 25476 -2.46 0.017291
apolipoprotein E 25728 -29.52 0.010995
Ubiquitin activity
Ubiquitin carboxy-terminal hydrolase L11 29545 -16.29 0.006928
Calcium ion binding
Phospholipase C, delta 41 140693 2.64 0.01117
Parvalbumin 25269 -3.85 0.004735
Purkinje cell protein 4 25510 -6.82 0.036186
Carboxylesterase activity
Carboxylesterase 11 29225 -2.16 0.038405
DNA repair
O-6-methylguanine-DNA methyltransferase1 25332 -4.62 0.006563
Enzyme inhibitor activity
Decay-accelarating factor 64036 4.02 0.002607
Glucuronosyltransferase activity
UDP glycosyltransferase 1 family, polypeptide A61 113992 -3.25 0.018816
Receptor activity
Coagulation factor II (thrombin) receptor-like 1 116677 4.96 0.017166
Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533
receptor, 5
Growth hormone receptor1 25235 -3.12 0.008131
Growth factor
Insulin-like growth factor 11 24482 -4.85 0.010787
Insulin-like growth factor binding protein 51,2 25285 -5.25 0.028276
Induction of apoptosis
Nerve growth factor receptor associated protein 11 117089 8.75 0.000319
1Genes found in the Cancer Genome Anatomy Project
2Genes found in the Prostate Expression database
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Kinesin complex
Peripherin 1 24688 -7.17 0.001239
Ligase activity
Asparagine synthetase1 25612 14.65 0.007699
Arginosuccinate synthetase1 25698 -12.75 0.006917
Lactate dehydrogenase activity
Lactate dehydrogenase B 24534 -15.07 0.013633
Phosphatase activity
Dual specificity phosphatase 61 116663 11.08 0.025634
Protein phosphatase 2 (formerly 2A), regulatory subunit B
(PR 52), beta isoform1 60660 2.31 0.00634
Protein tyrosine phosphatase, receptor type, N1 116660 2.22 0.029516
Transcription coactivator activity
Calcium/calmodulin-dependent serine protein kinase1 29647 -4.13 0.005154
Transferase activity
UDP glycosyltransferase 1 family polypeptide A21 396527 5.93 0.019318
Aminolevulinic acid synthase 11 65155 -2.39 0.015592
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 21 24450 -3.17 0.024703
Alcohol dehydrogenase activity
Alcohol Dehydrogenase 11 24172 -6.38 0.009355
Hydrolase activity
Adenosine monophosphate deaminase 31 25095 2.14 0.045491
Phosphodiesterase 3B1,2 29516 -4.76 0.024876
Fatty acid metabolism
Stearoyl-Coenzyme A desaturase 1 246074 25.92 0.031324
Other
Hypothetical LOC290595 (LOC290595), mRNA 290595 8.46 0.002463
Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) 316531 4.76 0.017132
(LOC316531), mRNA
Similar to chromosome 14 open reading frame 50 299153 3.58 0.019238
(LOC299153), mRNA
Guanine nucleotide binding protein beta 4 subunit 294962 3.38 0.017726
mRNA, partial cds
Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046
mediator protein (LOC363192), mRNA
Similar to cornichon-like protein (LOC361705), mRNA 361705 -2.35 0.004193
Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735
(RBP-MS) (LOC361161), mRNA
Similar to CLN6 protein (LOC315746), mRNA 315746 -3.68 0.00706
Reticulocalbin 3 308580 -3.94 0.027229
Similar to CG31613-PA (LOC364716), mRNA 364716 -8.61 0.047281
1Genes found in the Cancer Genome Anatomy Project
2Genes found in the Prostate Expression database
Table 3. Genes validated by qRT-PCR. Selected genes were validated by qRT-PCR.
Gene name Microarray qRT-PCR qRT-PCR
Fold change Fold change p value
Kelch repeat and BTB (POZ) domain containing 10 (krp1) 36.21 48 0.01816
Endothelial cell-specific molecule 1 26.5 23 0.00995283
Caveolin 1 31.05 45 0.0009527
Functional Group/ Entrez Fold P value
 individual genes genes change
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Overexpression of ESM-1 in the tumor tissue may
constitute a negative prognostic factor and a
marker for metastasis for cancer patients. This
concept has been suggested by others in cases
of breast cancer (28), renal cancer (29), and lung
cancer (30). However, the current study is the first
to link ESM-1 to metastatic prostate cancer.
Fibromodulin, overexpressed, and BGN and
decorin, underexpressed, are genes that encode
PG proteins that are members of the small leucine-
rich PG family. They function, under physiological
and pathophysiological conditions, as regulators
of matrix assembly, cellular adhesion, migration
and transforming growth factor beta (TGF-beta)
activity (31,32). In the current study, differential
expression of genes in the TGF-beta signaling
pathway was found as well (Table 1).
Other genes associated with cell-ECM interaction
are CD24 and Serpine 2. CD24 gene,
overexpressed in the current study, encodes a
small, heavily glycosylated and mucin-like cell
surface protein. CD24 has been found overexpres-
sed previousely in prostate cancers (33), and this
overexpression has been suggested as predictor
of prostate cancer relapse and poor prognosis (34).
Serpine 2 ( protease nexin I), found over expressed
in the current study, has been implicated in
invasive potential of pancreatic cancer cells
because it alters ECM production and organization
within the tumors (35). Serpine 2 mRNA levels
have been found overexpressed in prostate cancer
cell lines and possibly interacts negatively with
prostasin, an invasion suppressor protein (36).
Another overexpressed gene in the highly meta-
static MAT-LyLu cell line, was the Cav-1 gene.
Cav-1 was grouped in the regulation of cell prolif-
eration group and encodes a protein that is a com-
ponent of caveolae membrane coats. In human
and animal studies, Cav-1 was overexpressed in
metastatic prostate cancer; antisense-mediated
down regulation of Cav-1 in prostate cancer cells
in vitro seems to reduce the metastatic pheno-
type (37,38). Therefore, Cav-1 is considered a
metastasis-related gene in prostate cancers.
Finally, the most underexpressed gene was the
CD81 gene that encodes a cell-surface protein and
belongs to the tetraspanin superfamily (TM4SF).
Loss of CD81 has been found in poorly
differentiated hepatocellular carcinoma and
extrahepatic metastasis patients (39). CD81 has
not been associated with prostate cancer
previously; however, another member of the
tetraspanin family, KAI1/CD82, has been
suggested as a prostate cancer metastasis
suppressor gene. The underexpression of the CD81
gene in the current study warrants further
investigation to determine its exact function and
its potential as a suppressant of metastasis in
prostate cancer.
In summary, overexpressed and underexpressed
genes were successfully identified in a highly
metastatic rat prostate cancer cell line, when com-
pared to a non metastatic rat prostate cancer cell
line. The cell lines had been previously established
as in vitro models for studying prostate cancer.
To extrapolate results obtained from this work to
the human context, further studies are needed with
human samples and detailed clinical character-
ization of the patients for appropriate clinical cor-
relations. Nonetheless, the identification of genes
differentially expressed in these two rat cell lines
by DNA microarray analysis is a first logical step
in the search for dependable biomarkers for hu-
man prostate cancer metastasis.
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